Panacea Journal of Medical Sciences
Official Publication of NKP Salve Institute of Medical Sciences and Research Centre
Official Publication of NKP Salve Institute of Medical Sciences and Research Centre
Print ISSN:-2249-8176
Online ISSN:-2348-7682
CODEN : PJMSD7
Current Issue
Year 2024
Volume: 14 , Issue: 3
Viewed: 13
Emailed: 0
PDF Downloaded: 4
Full Text PDF Share on Facebook Share on Twitter
Original Article
Author Details :
Volume : 14, Issue : 3, Year : 2024
Article Page : 691-695
https://10.18231/j.pjms.2024.123
Abstract
Background: A widespread health issue in the world, diabetes mellitus is accompanied by a number of co-morbidities. Many antidiabetic drugs are available with different mechanisms of action and safety profiles. This study's goal was to assess the co-morbidities that type 2 diabetes patients experience & to evaluate current prescribing trends of antidiabetic drugs.
Materials and Methods: It was a cross-sectional study that was conducted in a tertiary care medical facility's outpatient department of medicine. It was six months conducted from July 2022 to December 2022. The approval of study, was taken from institutional ethics committee. The details of patients attending the outpatient department of medicine having diabetes mellitus with associated comorbidities are recorded in a case record form.
Results: Out of the 80 patients that were evaluated,48 (60%) were males and 32 (40%) were females. The commonly associated comorbidities found are hypertension in 82.5%, suffered from hyperlipidemia in 58.7%, and cardiovascular conditions in 46.2% later followed by others. Metformin in 81% followed by glimepiride + Metformin at 43%, Vildagliptin 26%, and Dapaglifozin 16%, followed by others were the commonly prescribed antidiabetic agents.
Conclusions: Hypertension, hyperlipidaemia & cardiovascular conditions were the commonly associated comorbidities with type 2 DM. Metformin followed by glimepiride+ metformin, Vildagliptin & Dapaglifozin were commonly prescribed. sodium-glucose co-transporter-2 (SGLT2) inhibitors and DPP)-4 inhibitors are potential new therapies with good safety profiles.
Keywords: Diabetes mellitus, Comorbidities, Dyslipidemia
How to cite : Siddiqui R A, Shende T R, Dashputra A V, Quazi S, Comorbidities associated with type 2 diabetes mellitus and the drug prescribing trends. Panacea J Med Sci 2024;14(3):691-695
Copyright © 2024 by author(s) and Panacea J Med Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)
